Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Status:
RECRUITING
Trial end date:
2029-12-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to evaluate the efficacy and safety of sintilimab combined with rituximab followed by R-CHOP regimen in treatment-nave patients with primary mediastinal diffuse large B-cell lymphoma. The main questions it aims to answer are:
1. Objective response rate of sintilimab combined with rituximab
2. Objective response rate after R-CHOP regimen